Understanding Zts Stock Symbol Zoetis Inc Performance

Zoetis Inc, the company behind the ZTS stock symbol, has been a leading player in the animal health industry for over a decade.

The company's strong performance can be attributed to its diverse portfolio of products, which includes vaccines, medications, and diagnostic tools for livestock and companion animals.

In 2013, Zoetis Inc was spun off from Pfizer, a move that allowed it to focus on its core business and expand its offerings.

This strategic move has paid off, with the company's revenue growing steadily over the years.

The current share price of ZTS stock is $170.42, which is a significant drop from its 52-week high of $200.53.

ZTS's beta is 0.89, indicating that it is less volatile than the overall market.

The company's 1-month change is a 3.54% increase, while its 3-month change is a -6.74% decrease. This suggests that the stock has been experiencing some fluctuations in recent months.

In the past year, the stock has decreased by 10.98%. However, over the past 5 years, it has increased by 22.63%.

ZTS's average weekly movement is 3.0%, which is lower than the pharmaceuticals industry average of 10.8% and the market average of 6.5%. This indicates that the stock is relatively stable.

Here's a comparison of ZTS's volatility with other stocks in the US market:

The stock has not had significant price volatility in the past 3 months compared to the US market, and its weekly volatility has been stable over the past year.

Zoetis's financial performance has been impressive, with revenue increasing by 5.74% in 2023 to $8.54 billion.

The company's earnings also saw a significant boost, rising by 10.88% to $2.34 billion in 2023.

Zoetis's financial strength is reflected in its cash-to-debt ratio, which stands at 0.25, indicating that for every dollar of debt, the company has 25 cents in cash.

The company's equity-to-asset ratio is 0.37, showing that for every dollar of assets, there is 37 cents in equity.

Zoetis's debt-to-equity ratio is 1.29, which is a relatively manageable level of debt compared to equity.

The company's debt-to-EBITDA ratio is 1.79, indicating that it takes 1.79 years of earnings before interest and taxes to cover its debt.

Zoetis's interest coverage ratio is a healthy 14.32, meaning the company has more than 14 times the earnings to cover its interest payments.

Here's a summary of Zoetis's financial health indicators:

Zoetis's Piotroski F-Score is 7/9, indicating that the company has a strong financial health profile.

The Altman Z-Score of 8.06 suggests that Zoetis is in a safe financial position.

The Beneish M-Score of -2.49 indicates that Zoetis is not a manipulator of its financial reports.

Analysts are overwhelmingly bullish on ZTS stock, with an average rating of "Strong Buy" from 8 analysts. This is a clear indication of their confidence in the company's future performance.

The 12-month stock price forecast is a whopping $215.38, which represents a 26.38% increase from the latest price. This suggests that analysts expect significant growth in the stock's value over the next year.

Here are some key analyst opinions that support this forecast:

These analyst opinions demonstrate a consistent and optimistic outlook for ZTS stock, with many analysts expecting significant growth in the company's value over the next year.

Analyst Forecast is a powerful tool for investors looking to make informed decisions about their stocks. Analysts from top firms like BTIG Research, HSBC, and Goldman Sachs have weighed in on Zoetis, and their opinions are worth considering.

According to 8 analysts, the average rating for ZTS stock is "Strong Buy". This is a clear indication of the confidence analysts have in Zoetis' future performance.

The 12-month stock price forecast is $215.38, which represents a 26.38% increase from the latest price. This is a significant potential upside for investors.

Here's a breakdown of the analyst ratings:

These analyst ratings and price forecasts provide valuable insights for investors considering Zoetis stock.

The Piper Sandler 36th Annual Healthcare Conference is a significant event in the industry, and Zoetis Inc. has participated in it. Zoetis will participate in the conference on Tuesday, December 3, 2024.

Wetteny Joseph, the Chief Financial Officer of Zoetis, will represent the company during the conference. He has a strong track record of providing valuable insights into the company's financial performance.

The conference is a great platform for investors and analysts to learn more about Zoetis' strategies and growth prospects. It's also an opportunity for the company to showcase its products and services.

Here is a list of Zoetis' past appearances at the Piper Sandler conference:

It's worth noting that Zoetis' participation in the conference may have a positive impact on the company's stock price. Analysts have consistently maintained a "Buy" rating for the company, with some even setting a price target of $260.